{"preliminary_commentary":{"by_channel":{"podcast":3,"x_thread":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sintilimab","IBI305"]],"indication":"first-line unresectable hepatocellular carcinoma","name":"ORIENT-32","nct_id":"NCT03794440","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=orient-32-nct03794440. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Sintilimab +IBI305","type":"EXPERIMENTAL"},{"description":null,"label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2022-12","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":595,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sintilimab","otherNames":["IBI308"],"type":"DRUG"},{"name":"IBI305","otherNames":["anti-VEGF monoclonal antibody"],"type":"DRUG"},{"name":"Sorafenib","otherNames":[],"type":"DRUG"}],"last_update":"2021-01-22","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","official_title":"A Randomized, Open-label，Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. （ORIENT-32）","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2022-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"up to 24 months after randomization"},{"measure":"Progression-free survival (PFS)","timeFrame":"up to 24 months after randomization"}],"references":[{"citation":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.","pmid":"34143971","type":"DERIVED"}],"start_date":{"date":"2019-02-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.","url":"https://clinicaltrials.gov/study/NCT03794440"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/orient-32-nct03794440"}